Tuesday, April 16, 2013

BEAT BioTherapeutics Raises $2.5M In Seed Funds For Heart Treatment

Seattle-based BEATbio, a biotechnology firm which says it is looking to develop a novel gene therapy to improve cardiac performance during heart failure, has raised $2.5M in a seed funding round. The firm said the funding came from CET Capital Partners and the W Fund. The company's technology was developed by a research team at the University of Washington in the labs of Charles Murry. The company said the funding will be used to move its lead gene therapy product into clinical development.